Press release
Lupus Nephritis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Take
Lupus Nephritis Pipeline Insights, DelveInsight
Lupus Nephritis Overview:
Lupus Nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that disrupts immune tolerance and leads to systemic autoimmunity, damaging multiple organs.
SLE affects approximately 7.4-159.4 people per 100,000, with a prevalence of 1.4% to 21.9%. LN, a type of glomerulonephritis, causes inflammation and scarring in the kidney's filtering units (glomeruli) and sometimes the entire kidney. It is classified into six histological classes, each representing varying levels of severity. The most serious form, proliferative nephritis, leads to kidney scarring and impaired function, potentially progressing to chronic kidney disease (CKD) or end-stage renal disease (ESRD), where the kidneys lose their ability to function entirely.
Request for a detailed insights report on Lupus Nephritis pipeline insights @ https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Lupus Nephritis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market.
Key Takeaways from the Lupus Nephritis Pipeline Report
DelveInsight's Lupus Nephritis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Lupus Nephritis treatment.
Key Lupus Nephritis companies such as Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others are evaluating new drugs for Lupus Nephritis to improve the treatment landscape.
Promising Lupus Nephritis pipeline therapies in various stages of development include Obinutuzumab, ADX-097, NKX019, and others.
Recent breakthroughs in the Lupus Nephritis Pipeline Segment:
In February 2024, the FDA granted Fast Track status to AlloNK, an experimental natural killer (NK) cell therapy developed by Artiva Biotherapeutics, for the treatment of lupus nephritis in combination with rituximab or obinutuzumab. This designation aims to expedite the development and review process, facilitating earlier access for patients. AlloNK is designed to enhance antibody-dependent cellular cytotoxicity (ADCC), potentially improving the efficacy of existing antibody-based therapies.
Lupus Nephritis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Lupus Nephritis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lupus Nephritis market.
Download our free sample page report on Lupus Nephritis pipeline insights @ https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Lupus Nephritis Emerging Drugs
Obinutuzumab: Hoffmann-La Roche
ADX-097: Q32 Bio
NKX019: Nkarta
Lupus Nephritis Companies
More than 35 key companies are actively developing therapies for Lupus Nephritis. Among them, Hoffmann-La Roche has a drug candidate in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight's report covers around 40+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Lupus Nephritis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Lupus Nephritis Therapies and Key Companies: Lupus Nephritis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Lupus Nephritis Pipeline Therapeutic Assessment
• Lupus Nephritis Assessment by Product Type
• Lupus Nephritis By Stage
• Lupus Nephritis Assessment by Route of Administration
• Lupus Nephritis Assessment by Molecule Type
Download Lupus Nephritis Sample report to know in detail about the Lupus Nephritis treatment market @ Lupus Nephritis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Lupus Nephritis Current Treatment Patterns
4. Lupus Nephritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Lupus Nephritis Late-Stage Products (Phase-III)
7. Lupus Nephritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lupus Nephritis Discontinued Products
13. Lupus Nephritis Product Profiles
14. Lupus Nephritis Key Companies
15. Lupus Nephritis Key Products
16. Dormant and Discontinued Products
17. Lupus Nephritis Unmet Needs
18. Lupus Nephritis Future Perspectives
19. Lupus Nephritis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Lupus Nephritis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Take here
News-ID: 3927629 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Lupus
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
